Stoke Therapeutics appoints Alexander “Bo” Cumbo to board after Edward Kaye resigns

By Public Technologies
  • Stoke Therapeutics appointed Alexander (Bo) Cumbo as a Class III director effective Sept. 23, 2026.
  • Edward M. Kaye resigned as a Class III director effective Sept. 23, 2026.
  • Kaye also stepped down from the board’s Research and Development Committee.
  • Cumbo was named to fill the vacancy, with a term running through the 2028 annual meeting.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-402820), on September 25, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk